Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Clinical trial NCT02398435 · COMPLETED

Trial details

NCT number: NCT02398435
Sponsor: AB2 Bio Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Still's Disease, Adult-Onset

Start date: 2015-02-01
Primary completion: 2016-06-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.